sábado, 2 de junio de 2018

NCI at ASCO - Dr. Sharpless Remarks and Saturday Sessions

ASCO Banner

NCI at ASCO 2018

Saturday, June 2

Today is the second day of the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting and we hope you join us in attending NCI Director Dr. Sharpless’ remarks this morning. 

You can also visit our experts at one of the NCI-featured sessions listed below, or stop by the NCI Exhibit Booth (#5041) for a “Meet the Experts” session, free publications, and more!

For more information about NCI activities at ASCO, visit the NCI at ASCO 2018 webpage.

NCI Director's Remarks

Dr. Ned Sharpless


At 10:25 AM, join NCI Director Norman E. Sharpless, M.D. at the ASCO Opening Plenary Session for the NCI Director’s Remarks.
To find out more about what Dr. Sharpless is up to at ASCO, follow @NCIDirector on Twitter.

NCI Speakers and Sessions at ASCO (Saturday)

Precision Medicine at NCI

Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial

Komal L. Jhaveri, M.D., FACP - New York University Cancer Institute
8:00 AM - 8:12 AM 

Results from molecular analysis for therapy choice (MATCH) arm I

Ian E. Krop, M.D., Ph.D. - Dana-Farber Cancer Institute
8:12 AM - 8:24 AM

Get up-to-speed with the latest results from the NCI-MATCH trial at the “Tumor Genomics: Finding the Target, Hitting the Target” session. From 8:00 AM – 8:24 AM, two NCI grantees will discuss “Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophogeal junction (GEJ) adenocarcinomas,” and “Taselisib for PIK3CA-mutated tumors.”

For more information on MATCH, visit the NCI-MATCH Trial webpage

Nonimmunotherapy Strategies in Advanced Bladder Cancer

Andrea Apolo, M.D.9:36 AM - 9:48 AM
Listen to NCI’s Dr. Apolo discuss three of the abstracts presented during the "Genitourinary (Nonprostate) Cancer" session: 450345044505.

NCI Director’s Remarks

Norman E Sharpless, M.D.
10:25 AM - 10:50 AM
Join NCI Director Dr. Sharpless for his remarks during the ASCO Opening Plenary Session.

Immunotherapy and Other Mesothelin-Targeted Agents for the Treatment of Malignant Mesothelioma

Raffit Hassan, M.D.
1:35 PM - 1:55 PM
At the “Malignant Mesothelioma: Therapies to Get Really Excited About” session, Dr. Hassan will present on immunotherapy and other exciting treatments for malignant mesothelioma. 

Surgeons in a Circle

Is There a Role for Adoptive Cell Therapy in the Treatment of Melanoma?

Stephanie Goff, M.D.
3:40 PM - 4:00 PM
Want to learn more about adoptive cell therapy in treating melanoma? Come to Dr. Goff’s presentation during the “Emerging Personalized Strategies in Systemic Therapy for the Treatment of Melanoma” education session.

SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN) 

Andrea Gross, M.D., B.S.
4:00 PM - 4:12 PM
Plexiform neurofibromas (PN) in children with neurofibromatosis type 1 (NF1) can cause substantial morbidity, and there are no approved medical therapies. Join Dr. Gross as she presents her abstract on a phase II study that examined the partial response rate of PN treated with selumetinib and changes in PN related morbidities.

Hairy Cell Leukemia

Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia: Results of a pivotal international study 

Robert Kreitman, M.D.
4:12 PM - 4:24 PM
At the “Hematologic Malignancies” oral abstract session, Dr. Kreitman will present his abstract on a pivotal multicenter, single-arm study that evaluated moxetumomab pasudotox, a first-in-class recombinant immunotoxin, in patients with relapsed/refractory hairy cell leukemia.

Treatment of metastatic human papillomavirus-associated epithelial cancers with adoptive transfer of tumor-infiltrating T cells

Sanja Stevanovic, Ph.D.
4:12 PM - 4:24 PM
Adoptive T-cell therapy (ACT) is a promising cancer treatment modality. However, its study in epithelial cancers has been limited. At this session, NCI’s Dr. Stevanovic will present her abstract on a clinical trial of ACT for the treatment of metastatic HPV-associated cancers.

Activities at the NCI Exhibit Booth (#5041)

NCI Meet the Experts

Want to learn more about what's happening across the National Cancer Institute? Attend a "Meet the Experts" session!

Check out the Saturday "Meet the Experts" schedule on the NCI at ASCO 2018 webpage.
We look forward to seeing you at the booth!

No hay comentarios:

Publicar un comentario